Shots:
- The P-II/III study evaluates opaganib +SoC vs PBO + SoC in a ratio (1:1) in 475 patients with COVID-19 pneumonia requiring hospitalization & treatment with supplemental oxygen
- The preliminary data showed that the study did not meet its 1EPs while efficacy EPs showed consistent trends. The therapy demonstrated good tolerability with balanced AEs & increased the benefit for patients requiring less oxygen at earlier stages of the disease
- Opaganib is an SK2 selective inhibitor with dual anti-inflammatory & antiviral activity. The therapy has been approved in South Africa & expansion within the US while the company plans to discuss data with regulators to determine the next steps
Click here to read full press release/ article | Ref: PR Newswire | Image: PR Newswire
The post RedHill’s Opaganib (ABC294640) Fails to Meet its Primary Endpoints in P-II/III Study for the Treatment of Severe COVID-19 first appeared on PharmaShots.
